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Abstract: Guanidinium toxins, such as saxitoxin (STX), tetrodotoxin (TTX) and their analogs, are
naturally occurring alkaloids with divergent evolutionary origins and biogeographical distribution,
but which share the common chemical feature of guanidinium moieties. These guanidinium groups
confer high biological activity with high affinity and ion flux blockage capacity for voltage-gated
sodium channels (NaV). Members of the STX group, known collectively as paralytic shellfish toxins
(PSTs), are produced among three genera of marine dinoflagellates and about a dozen genera of
primarily freshwater or brackish water cyanobacteria. In contrast, toxins of the TTX group occur
mainly in macrozoa, particularly among puffer fish, several species of marine invertebrates and a
few terrestrial amphibians. In the case of TTX and analogs, most evidence suggests that symbiotic
bacteria are the origin of the toxins, although endogenous biosynthesis independent from bacteria
has not been excluded. The evolutionary origin of the biosynthetic genes for STX and analogs in
dinoflagellates and cyanobacteria remains elusive. These highly potent molecules have been the
subject of intensive research since the latter half of the past century; first to study the mode of action of
their toxigenicity, and later as tools to characterize the role and structure of NaV channels, and finally
as therapeutics. Their pharmacological activities have provided encouragement for their use as
therapeutants for ion channel-related pathologies, such as pain control. The functional role in aquatic
and terrestrial ecosystems for both groups of toxins is unproven, although plausible mechanisms
of ion channel regulation and chemical defense are often invoked. Molecular approaches and the
development of improved detection methods will yield deeper understanding of their physiological
and ecological roles. This knowledge will facilitate their further biotechnological exploitation and
point the way towards development of pharmaceuticals and therapeutic applications.
Keywords: saxitoxin (STX); paralytic shellfish toxin (PST); tetrodotoxin (TTX); guanidinium; neurotoxin;
voltage-gated sodium channels; ion channels
1. Introduction
Many living forms have developed complex neurological systems to receive and transduce vital
information from the environment where they live and to elicit appropriate behavioral responses to
such stimuli. Generation of neuro-electrical signals is crucial not only for sensory functions including
transmission and processing of information in the neurological center (or brain), but also for muscle
contraction, secretion of hormones and distributing response signals to the rest of the tissues. All these
electrical signals are conducted by members of the ion channel protein superfamily, comprising more
than 140 structurally related pore-forming proteins [1].
Voltage-gated ion channels are the target for a wide range of naturally occurring toxins, including
guanidinium and secondary amine analogs and various polypeptide and protein neurotoxins. Among
Mar. Drugs 2017, 15, 303; doi:10.3390/md15100303 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2017, 15, 303 2 of 28
the voltage-gated ion channels, the voltage-gated sodium channel (NaV) family was the first to be
discovered. These associated proteins are thus considered the founding members of the ion channel
superfamily [2]. The NaV pore proteins allow the rapid influx of Na+ ions across the cell membrane,
typically with a compensatory efflux of K+ ions via the respective ion channel. Establishment and
collapse of the electrochemical charge gradient across cell membranes generates an ionic imbalance
responsible for the initiation of action potentials in nerve, muscle and endocrine cells of animals [3].
The guanidinium neurotoxins, namely saxitoxin (STX), tetrodotoxin (TTX), and their numerous
analogs, are naturally occurring alkaloids with a high affinity for binding to NaV channels, thus
blocking the influx of Na+ ions into the cell. This blockage inhibits the propagation of action potentials
in excitable membranes, and this impediment causes effective neuro-muscular paralysis. These
toxins have been intensively studied because of their effects on human health after consumption of
toxin-contaminated seafood, and morbidity and mortality of primarily marine vertebrate species of
fish, mammals and seabirds. More recent research efforts have focused on determining their critical
eco-evolutionary roles in the chemical ecology and species interactions in natural marine, freshwater
and terrestrial ecosystems.
Toxic events putatively caused by STX and TTX from natural sources have been well documented
throughout recorded history and are part of the folkloric traditional knowledge of many indigenous
populations. Ancient societies including the Egyptian, Greek, Chinese and Mayan civilizations
knew about the toxic properties of certain puffer fishes, presumably containing TTX based upon the
characteristic symptomology [4,5]. The use of puffer fish extracts as a key ingredient in zombification
preparations for voodoo rituals has been widely known for centuries in the Caribbean [5]. Among
certain native populations of the Pacific northwest of North America, wild shellfish consumption
is traditionally avoided during periods of “shiny water”, or bioluminescence caused by certain
dinoflagellates. Blooms of the STX-producing dinoflagellate Alexandrium catenella have been recognized
as a major contributor to natural surface ocean bioluminescence and simultaneously to high shellfish
toxicity in the northwest Pacific region for many decades [6]. Within the last 50 years, such dinoflagellate
blooms known to produce to STX analogs have apparently expanded in biogeographical range, and have
contributed to increased magnitude and frequency of toxic events around the world.
2. Origin and Proximal Sources of Guanidinium Toxins
Toxin analogs belonging to the STX and TTX families share common guanidinium moieties
(Figure 1), which accounts for their neurotoxicity and similar molecular targets, but these toxin groups
differ widely in organismal origin and biogeography. The distribution of TTX and its analogs is
highly diverse, as these toxins can be found in aquatic and also in terrestrial environments. Human
intoxications by TTX are most often linked with the consumption of certain puffer fish species from
the marine environment, particularly in tropical and sub-tropical regions; hence the syndrome is often
referred to as “puffer fish poisoning” (PFP) [7]. Nevertheless, recent detection of TTX in gastropods [8,9]
and in bivalve mollusks from Europe [10,11] at levels of concern for human consumers of seafood,
suggests that the risk may be more widespread than formerly assumed.
For a long time it was believed that TTX was produced exclusively by fishes of the family
Tetraodontidae, but now this toxin and its analogs are known to occur in a wide diversity of often
phylogenetically unrelated organisms [14] of either terrestrial or marine origin. In addition to bacteria,
these include species of newts, crabs and frogs, as well as some gastropods, bivalve mollusks, sea
slugs, star fishes, blue-ringed octopus and ribbon worms [15–22]. During most of the 20th century
there was a raging debate regarding the origin of TTX in marine and terrestrial fauna—endogenously
produced by metazoa or by epi- or endo-symbiotic bacteria or exclusively by free-living bacteria
harbored briefly during gut passage of ingested food. Now it is known that most (perhaps all) marine
metazoa do not themselves produce these toxins, but rather they are synthesized by different genera
of bacteria [22,23]. In the marine environment, TTX-producing bacteria most frequently belong to
species of Actinomyces, Aeromonas, Alteromonas, Bacillus, Pseudomonas and Vibrio, among other common
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genera [24]. Marine fauna acquire the toxin-producing bacteria via the food web, whereby the bacteria
can persist in their guts, or by parasitism or symbiosis, with the bacteria lodged within or on their
skin [24–26]. In these cases, the metazoa merely serve as vectors or hosts for the toxigenic bacteria.
A few studies have suggested an endogenous origin of TTX for certain puffer fish species, such as
Takifugu (=Fugu) niphobles [27], but this is considered a rare case and requires further confirmation.
Knowledge of the origin and distribution of TTX among terrestrial toxic organisms is rather different;
to date no TTX-producing bacteria have been isolated from any amphibian species that possesses this
toxin [17,28]. This has led to the hypothesis that TTX production in these organisms is endogenous as
a defense mechanism, and that extant bacteria are no longer involved in their biosynthesis, although
the biosynthetic genes may have been originally bacterial. Curiously, TTX appears to be essentially
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Figure 1. Structure and ionization of the guanidinium group. Saxitoxin (STX) has two guanidinium
moieties and therefore two dissociation constants: pKa 8.22 for the 7,8,9 guanidinium group and 11.28
for the 1,2,3 group [12]. Tetrodotoxin (TTX) has only one guanidinium moiety, with a pKa of 8.76. These
groups are protonated under physiological conditions, with a +1 charge [13].
Saxitoxin and its analogs are alternatively known as “paralytic shellfish toxins” (PSTs) because
they cause the syndrome known as “paralytic shellfish poisoning” (PSP) in human consumers
of toxin-contaminated s afood. The PSTs accumulate in many marine species via the food web,
particul rly in bivalve shellfish by suspension-fe ding on toxic dinoflagellates, but also in cru taceans
and gastropods. The toxi s ay be transferred to marine mammals and se bird that fe d by diverse
mechanisms on zooplankton, mollusks, ichthyoplankton and fish. In the sea, PSTs are produced
by me bers of three genera of free-living marine dinoflagellates associated with harmful algal
blooms (HABs): these include about a dozen species of Alexandrium, and a single species each of
Gymnodinium (G. catenatum), and Pyrodinium (P. bahamense var. bahamense) [29,30]. According to a
review by Hallegraeff [31], close to 2000 PSP cases are reported yearly around the world, with a mean
fatality rate of about 15%. Children are known to be more susceptible and suffer a higher fatality
rate [32], which is only partially attributable to their generally lower body mass.
Many species of brackish and freshwater filamentous cyanobacteria [28,31–33] from the orders
Oscillatoriales and Nostocales are also capable of producing STX and analogs, but they are
phylogenetically unrelated to the toxigenic dinoflagellates in the ocean and tend to occupy different
habitats. Various strains of species within the cyanobacterial genera Cylindrospermopsis, Dolichospermum
(previously Anabaena [33]), Aphanizomenon, Planktothrix and Lyngbya [34,35] are known to biosynthesize
PSTs, even in the absence of other ass ciat d bacteria. Although o acute human PSP events have been
recorded from freshw ter systems, e.g., from co sumption of fish or crustaceans, th re have been cases
of livestock poisoning by drinking from freshwater bodies during high gnitud cyanobac ial
blooms containing PSTs [36]. The presence of these toxins is also of concern regarding drinking water
supplies for huma s and for wild animals. Recreational water resources can e also affected by the
presence of cyanobacterial blooms containing PSTs [37]. There are many known cases of contact toxicity
and skin irritation linked to cyanobacterial blooms, but because some cyanobacteria produce multiple
toxins the exact role of PSTs in these syndromes has not been established. There is little research on
contact expose to PSTs released from algal blooms and it is yet unknown if these toxins are effectively
transferred to humans via this route.
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3. General Chemical and Toxicological Properties of Guanidinium Toxins
Toxin molecules from the STX and TTX groups share a number of chemical properties that account
for their toxicity. They are heat stable alkaloids, and thus cooking or boiling food bearing the toxins
will not generally lead to sufficient loss or deactivation of the toxins to prevent poisoning the consumer.
The PSTs are subject to thermal decomposition under alkaline conditions, but this tends to render the
food inedible. These toxins are rather water-soluble and therefore some toxin will be extracted during
cooking in liquid; if the liquid fraction is then discarded, the net toxicity of the food will be somewhat
reduced. This is, however, not a reliable method of toxicity reduction and in fact heating, especially
under mild acidic conditions, tends to convert the PSTs to more toxic analogs.
The guanidinium toxins are small molecules with low molecular weight (typically between
200 and 600 Da) and are not known to form macromolecular complexes. Compared to other NaV
channel blockers, such as the µ-conotoxin group of polypeptide toxins from marine mollusks, it is
amazing how these tiny structures, formed by less than twenty carbon and three to five nitrogen atoms,
plus hydrogen and oxygen, are capable of blocking the NaV channels with such high affinity to cause
neurological symptoms that can lead to death in severe cases of exposure.
Members of the STX group bear two guanidinium groups, whereas TTXs bear only one (Figure 1).
This chemical characteristic confers either one or two positive charges to the molecules at physiological
pH, which has important implications for their toxicity [38]. To date, the STX group is represented by
more than 50 natural analogs, comprising the PSTs synthesized and metabolized by dinoflagellates
and cyanobacteria, plus analogs created via biotransformation in other species [37] (Figure 2).
The TTX group comprises more than 25 natural analogs found among marine and terrestrial
fauna and associated bacteria, plus synthetic analogs [24] (Figure 3).
Synthetic analogs of both toxin groups have been produced to study the biosynthetic pathways
and to explore specific toxicity and potential therapeutic applications. In any case, the discovery of new
natural guanidinium toxins has not been exhausted; the major analogs of human health significance
have likely been identified and structurally characterized but further metabolites of unknown toxicity
will undoubtedly be uncovered.
Guanidinium toxins are considered amongst the most potent known natural toxins, with lethal
dosages for humans in the low milligram range for the most toxic analogs of TTX [22] and STX [37]
(Tables 1 and 2).
Table 1. Relative acute toxicities of STX (=1.0) and some derivatives according to intraperitoneal
mouse bioassay (IP MBA) data compiled by Durán-Riveroll et al. [39] with values calculated
from * Sullivan et al. [40] and ** Oshima [41]. Relative oral toxicity values in mice by voluntary
feeding/gavage are according to Munday et al. [42].
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B1    0.1    0.06/0.05   
B2    0.1    <0.02/0.04   
C1    0.01 ** 
C2    0.1     
C1/2      0.04/0.03 
C3    0.01 ** 
C4    0.1     
 
Figure 2. Saxitoxin and major naturally‐occurring analogs produced among marine dinoflagellates, 
various  freshwater  and  brackish  water  cyanobacteria  (e.g.,  LWTX1‐LWTX6  from  Lyngbya)  and 
Figure 2. Saxitoxin and aj t ll -occu ring analogs produced among marine dinoflag llates,
various freshwater and br ter cyanobacteria (e g., LWTX1-LWTX6 from Lyngbya) and
metabolic transformation products (e.g., M-toxins) found in mussels (Mytilus). Left: the 3,4,6-trialkyl
tetrahydropurine skeleton with two guanidinium groups, common to all STX analogs. STX, saxitoxin;
NEO, neosaxitoxin; GTX1-4, gonyautoxins 1 to 4; B1, B2, toxins B1 and B2; C1-C4, toxins C1 to
C4; dcSTX, decarbamoyl saxitoxin; dcNEO, decarbamoyl neosaxitoxin, dcGTX1-4, decarbamoyl
gonyautoxins 1 to 4; LWTX1-6, lyngbyatoxins 1 to 6; M1-M4, Mytilus toxins 1 to 4. Asterisks* for
the GC-toxins refer to putative structures determined primarily by LC-MS/MS, with NMR support in
some cases, but which remain to be confirmed.













Table  2.  Acute  toxicity  of  guanidinium  toxins  and  the  NaV  blocking  protein  μ‐conotoxin  (for 
reference) in different animal models and via various routes of administration. LD50 is defined as the 
dose  that causes death of 50% of  the  test subjects under  the specified administration conditions. * 
intramuscular injections were intended to directly expose the sciatic nerve to STX [43]. O, oral; i.v., 
intravenous;  i.p.  intraperitoneal;  i.m.,  intramuscular;  s.c.,  subcutaneous; i.g.,  intragastric;  O/G, 
oral/gavage; O/F, oral/feeding. 

































Figure 3. Tetrodotoxin (TTX) and analogs. The asterisks* indicate synthetic analogs, whereas those
without asterisks refer to major naturally occurring compounds.
Table 2. Acute toxicity of guanidinium toxins and the NaV blocking protein µ-conotoxin (for reference)
in different animal models and via various routes of administration. LD50 is defined as the dose that
causes death of 50% of the test subjects under the specified administration conditions. * intramuscular
injections were intended to directly expose the sciatic nerve to STX [43]. O, oral; i.v., intravenous;
i.p. intraperitoneal; i.m., intramuscular; s.c., subcutaneous; i.g., intragastric; O/G, oral/gavage; O/F,
oral/feeding.













































[47] [47]11-deoxyTTX i.p. 231
µ-conotoxin GIIIA i.p. 1066
[48]
µ-conotoxin GIIIB i.p. 345
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As the only marine natural product declared a chemical weapon [49], STX has been placed on
Schedule 1 of the Chemical Weapons Convention [50]. Toxin potency in mammalian systems varies
with structural differences among analogs from both STX and TTX group [38]. Among the STX group,
the carbamoyl derivatives are typically the most potent, with decarbamoyl analogs of intermediate
potency and N-sulfocarbamoyl analogs much less toxic. The deoxy analogs of TTX are typically less
toxic than TTX, whereas the hydroxyl analogs, acting as hydrogen bond donors, are more toxic because
of enhanced binding to NaV channels [24]. Extensive toxicity studies have not been conducted with all
the natural analogs of either guanidinium toxin group, mainly due to the lack of sufficient purified
toxins. Nevertheless, in cases where empirical toxicological data are not available, their structures
provide information to generate hypotheses about their potency based upon binding simulations [39].
4. Symptomology and Etiology of Exposure to Guanidinium Toxins
At the physiological level, there is little to distinguish the effects of TTX versus STX poisoning in
humans or among other higher vertebrates with comparable neuro-muscular systems, other than the
fact that with PSP as opposed to TTX poisoning there is rarely significant hypotension. In humans,
guanidinium toxin poisoning elicits a series of distinctive symptoms: around 30 min after consumption
of the toxic food (and depending on the dosage), the victim begins to experience a characteristic
sequence of paresthesias: tingling of tongue and lips, and sometimes in other tissues if the victim
has been in contact with the toxin near an open wound (even a superficial cut). These tingling
symptoms can be followed by a sensation of floating, headache, vomiting, muscle weakness and a
lack of muscle control or coordination of voluntary movements (ataxia) that can cause difficulties
with speech, eye movement and swallowing. These sensations and effects may reach extremities, even
fingers and toes. After a while (typically a few hours), paralysis starts, and voluntary movements are lost,
but consciousness remains unaffected. With high doses, death may occur due to paralysis of the muscles
involved in respiration, such as the diaphragm [43,51]. The lethal oral dose in humans is approximately
1 to 4 mg STX depending upon the age, individual susceptibility and physical condition of the victim.
Analysis of tissue and body fluids from fatal PSP victims have shown distribution of the toxins in
brain, bile, cerebrospinal fluid, liver, spleen, heart, thyroid and adrenal glands, kidneys, pancreas and
lungs [52]. This systemic distribution is primarily due to the high mobility and hydrophilic nature of
the toxins and explains the neurological and gastrointestinal symptoms. The guanidinium toxins are
capable of crossing the blood-brain barrier, at least in high doses [53].
To date there is no known targeted antidote for acute guanidinium toxin poisoning. Anticurare
drugs are known not be effective, whereas administration of anticholinesterase agents previously
tried as therapeutants, such as the nonselective muscarinic acetylcholinergic antagonist atropine,
can actually be counter-productive. The ineffective or counterproductive role of anti-cholinesterase
agents in TTX or STX poisoning remains poorly defined but may be due to the fact that the toxin
blockade leading to paralysis is not antagonized by anticholinesterase agents. At least in the case of
TTX poisoning, neuromuscular transmission is interrupted at the motor axon and muscle membrane
and not at the end plates (cited in [54]). The stimulant DL amphetamine (benzedrine) may, however,
provide supportive aid during artificial respiration and in reducing the recovery period. The poisoning
victim requires immediate medical attention, often with respiratory assistance. In some cases, oral
administration of activated charcoal to capture remaining toxin that has not yet been taken up from
the victim’s digestive system and/or gastric lavage with antacid agents such bicarbonate can aid in
mitigating symptoms. Residual symptoms can remain for up to a week, but no long-term clinical
effects have been reported [49,55].
Fatalities after acute exposure to PSTs are rather uncommon in countries with a well-administered
toxin surveillance program for seafood, but low dosage extended exposure to the toxins may frequently
occur in communities that depend primarily on seafood for subsistence. The annual intake of
potentially toxin-contaminated seafood in these indigenous communities is by far greater than average,
and natives may chronically consume untested shellfish containing low toxin doses. The claim that
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PST tolerance can occur [56] may indicate that individuals frequently and chronically exposed to
sub-lethal doses of the toxins could ingest amounts higher than safety guidelines with no deleterious
symptoms [53], although controlled epidemiological studies are lacking to confirm this response.
In any case, the mechanism of such putative toxin resistance is not understood, but is unlikely to be
immunogenic because of the small molecular size and non-proteinaceous nature of the PSTs.
Although subtle low dosage adverse effects may occur, there is little research on guanidinium toxin
effects at low-chronic doses in humans. Studies on rat cortical neurons showed that chronic exposure
to TTX cause dendrite retraction, loss of dendritic spines and degeneration of the neurons within a
period of 1–2 weeks, as well as apoptotic processes triggered by miniature excitatory postsynaptic
currents [57]. Experimental work on neurites indicated that long-term exposure to low doses of
guanidinium toxins could affect neurogenesis during CNS development [58].
Apparently, chronic exposure to guanidinium toxins does not exclusively affect the nervous
system. The possibility that these toxins could have adverse effects on other physiological systems is
supported by the observed reduction in metabolic enzyme activity in different animal models; there is
also the potential for enzyme polymorphisms that could yield inter-individual differences in response
to STX [53]. In some wild fish, adverse effects such as epithelial hyperplasia in the gills and liver
necrosis have been observed after extended exposure to low doses of PSTs [59]. Fish and mammalian
in vivo models have shown both significant changes in antioxidant mechanisms and DNA damage
in response to these toxins [60,61]. Antioxidant enzymes were significantly reduced in the liver of
mice exposed to low (sub-lethal) concentrations of the epimeric pair GTX 2/3; a similar effect was also
noted when the less toxic analogs C1/2 were administered [60]. Drinking water spiked with STX and
provided to laboratory rats for 30 days induced changes in the antioxidant mechanisms in brain and
liver [62]. These changes could cause an increase in oxidative stress [63], although how PSTs could
directly or indirectly mediate these reactions is still unknown. All these results point to the possibility
that low-dose exposure to guanidinium toxins, even when unnoticed, could still have critical long
term physiological consequences, and not only within the nervous system.
5. Mode of Action and Ion Channel Targets
Sodium ion channels are molecular targets for many marine neurotoxins, but the binding sites,
relative affinities and toxic potency are specific for the respective pharmacophore and hence elicit
widely different pharmacological responses. The potent dinoflagellate polyketide palytoxin, for
example, targets the Na+:K+ ATPase [64], which is not a voltage-gated channel, whereas STX can
interact with voltage-gated Na+, Ca2+ and K+ ion channels to a greater or lesser extent, with potency
determined by the structure and polarity of the individual analogs. Interaction of STX with the human
ether-á-go-go (hERG) potassium channel has been reported [65], with the mechanism of inhibition of
the channel by STX described as completely distinct from the way in which it inhibits NaV channels.
The hERG K+ channels are inhibited by modifying channel gating rather than by blockage of the pore,
and not one, but four or more toxin molecules are able to bind to these channels [65,66]. The action
of STX on calcium channels has also been proven. The effect of STX on L-type calcium channels
(L-Type ICa) is via the reduction the Ca2+ currents for this type of channel in ventricular myocytes, but
this effect has not been observed with TTX; it is possible that these channels possess a binding site for
STX but not for TTX [67].
In any case, the guanidinium moieties (Figure 1) on STX and TTX analogs are the pharmacophores
responsible for the blocking activity on the NaV channels. These guanidinium groups, comprising a
central carbon atom and three nitrogen atoms with a positive charge at physiological pH, confer the
binding capacity to Site 1 of the NaV, thereby partially or completely blocking the inward Na+ ion
current. The guanidinium toxins are known to elicit a multiplicity of effects on various ion channel
types, but their primary toxic effects are mediated via voltage-gated ion channel blockage, specifically
by binding to the NaV channels of excitable cells, mainly in muscles and nerves. Blockage of Na+ ion
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entry affects the sensory systems, muscles and nerves of most animals, but particularly vertebrates [68]
with highly sophisticated and differentiated neurological systems.
Prior to empirical knowledge of the mode of action of guanidinium toxins, ion channels were
essentially unknown. The discovery that these toxins interfered with the generation of action potentials
in nerves and voluntary muscles with high potency [69] led to numerous investigations on the
electrophysiological mechanisms and structures involved in the generation of action potentials.
Application of a voltage-clamp technique with lobster axon preparations showed a specific potent
action of TTX in preventing the increase of Na+ ion conductance associated with the so-called, “sodium
carrying mechanism”. This early pioneering study by Narahashi and co-workers [70] initiated further
studies on what later would be called ion channels. Soon thereafter it was noted that both guanidinium
toxins (STX and TTX) shared similarities in mode of action, by interfering with the production of action
potentials in nerves and skeletal muscle at nanomolar concentrations. These toxins became useful
additions to the arsenal of pharmacological tools in the study of the molecular structure of excitable
membranes [71]. Later studies confirmed that the positive charges of the guanidinium groups were
substantially responsible for elicited toxicity, and this led to the discovery of the ion channel families.
The guanidinium groups fit the external orifice of the NaV channels but the toxin molecule is too
large to penetrate the pore, resulting in the clogging of the ion passage [70,72]. Channel isoforms are
now classified in terms of “sensitive” or “resistant”, depending on the binding affinity of TTX [73]
(Table 3). This sensitivity property is the result of point amino acid substitutions in the ion channel
structure but is only beginning to be understood in the context of evolutionary origin and physiological
significance [69].
Some predators that fed on highly toxic prey, such as newts of the genus Taricha, which are known
effective TTX producers, have evolved resistance to high levels of the toxin. For example, certain amino
acid sites have been identified in the NaV1.4, 1.6 and 1.7 that confer resistance to TTX for the garter
snake Thamnophis sirtalis, a newt predator. These channel isoforms are found in the muscle as well as
in the peripheral nervous system, where they can be exposed to the ingested toxin, and thereby they
have evolved resistance. Central nervous system ion channels, such as NaV1.1–1.3, have not shown
any resistance to TTX, and this is consistent with protection from toxin exposure by the blood-brain
barrier [74].
Voltage-gated sodium channels are pore-forming membrane proteins that consist of a single
protein complex that forms one α- subunit of 220–260 kDa and one to three auxiliary β-subunits of
approximately 33–36 kDa [3,76]. The α-subunit comprises four homologous domains (I–IV), that
are thought to form a circumference around the ion-conducting pore. Each domain contains six
hydrophobic transmembrane segments (S1–S6) (Figure 4). Two of these segments (S5 and S6) form
the internal portion of the pore, and have a membrane-reentrant loop between them, called the
P-loop. These P-loops form the fine extracellular end of the pore (Figure 5). The β-subunits are small
proteins that interact with the α-subunits, altering their physiological properties and their localization,
but they do not have an active relationship with the ion influx. These subunits are considered to
be a recent evolutionary addition to the pore-forming proteins and have only been identified in
vertebrates [3,77,78].
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Table 3. Classification of NaV channel isoforms according to their sensitivity to TTX [72,73,75]. CNS,
central nervous system; PNS, peripheral nervous system; SMCs, smooth muscle cells; DRG, dorsal root
ganglion. IC50 (half maximal inhibitory concentration) is the dose that inhibits by 50% the biological
function under the specified administration conditions.
NaV Channel Isoform Predominant Location TTX IC50 [nM] Sensitive/Resistant
NaV1.1 CNS, PNS, Heart 5.9 Sensitive
NaV1.2 CNS 7.8 Sensitive
NaV1.3 CNS (embryonic) 2.0 Sensitive
NaV1.4 Skeletal muscle 4.5 Sensitive
NaV1.5 Heart, CNS 1970 Resistant
NaV1.6 CNS, PNS, SMCs, DRG 3.8 Sensitive
NaV1.7 PNS, DRG 5.5 Sensitive
NaV1.8 PNS, DRG 1330 Resistant
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Figure 5. Schematic figurative representation of the α-subunit of the NaV channel. The protein structure
shows the location of Site 1, the binding site for STX and T their respectiv analogs.
To date, nine N V α-subun ts have b en fully functionally characterized and designa ed: NaV1.1
to 1.9, comprising a single family of proteins [2]. The α-subu its differ in terms of tissue distribution in
adults a d developing organisms, pharmacological and electrophysiological pro erties, and response
to nerve injuries [79]. All cells containing NaV channels co-express multiple isoforms [80].
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The NaV channels have a selectivity filter that allows the entry of Na+ ions and inhibits the
entrance of other positively charged molecules/ions. This filter consists of one amino acid from each of
the four domains (I–IV), respectively: Asp (D)–Glu (E)–Lys (K)–Ala (A) (called the DEKA motif) [39];
this DEKA motif comprises one residue from each of the four P-loop regions. Mutational and binding
mapping studies led to the identification of the four main residues in the selectivity region located on
the outer portion of the pore [81–85]. Three positions from the DEKA motif there is a ring of negatively
charged amino acids (Glu (E)–Glu (E)–Met (M)–Asp (A) in mammals) that creates an electrostatic cloud
to attract the Na+ ions into the pore [86]. Any alteration of the amino acids forming the DEKA moiety
of the selectivity filter, or in this charged ring, can reduce the Na+ ion conductance across the pore [87].
The binding site for guanidinium toxins is located in the α-subunit, specifically in the outer
vestibule, a water-filled region formed by the four P-loops [82]. This is the binding Site 1, which is
blocked specifically by guanidinium toxins (Figure 5). The affinity of these toxins in the NaV channel is
1:1; this means that one molecule binds to one ion channel, blocking it completely or partially [81,88].
Different analogs are considered to bind to the same site in the pore, but with different affinities
depending on the functional groups present for each analog. One hypothesis for potency differences
among the STX analogs is that they are due to steric hindrance effects, whereby larger functional
groups such as sulfate or benzoyl moieties interfere with the blocking capacity (Figure 6). Nevertheless,
this has not been proven, and there are alternative hypotheses about differences in the mode of binding
of TTX versus STX and their respective analogs [89]. An alternative, but not mutually exclusive,
hypothesis is that lesser potency is due to the compensatory reduction of the net positive charges,
and consequent reduced affinity for the Site 1 when the molecule has functional groups with negative
charges that balance the net charge [39], e.g., in the case of the N-sulfocarbamoyl C-toxins.
Recent studies [89] have shown that there are unexpected differences in affinity for STX analogs
and TTX among certain NaV isoforms. Walker et al. [89] demonstrated that whereas rat NaV1.4 and
human NaV1.7 showed comparable affinity to TTX, their affinity to STX exhibited a 250-fold difference
between both isoforms. In comparative analyses of the channel amino acid sequences they identified
two amino acid variations in the α-subunit, and this variation was unique for NaV1.7 in humans and
other primates. Through electrophysiology experiments with mutant forms of both channel isoforms,
they proved that specific amino acid substitutions are important modulators of STX affinity to NaV.
These results are a challenge to the conventional belief that both guanidinium toxin groups have
comparable activities for all channel sensitive isoforms, and demonstrate the need for deeper research
to fully understand the interactions between guanidinium toxins and NaV channels.
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Figure 6. Schematic figurative representation of the NaV channels in a neuronal cell membrane.
(A) Normal Na+ ion flux through the pores; (B) NaV channels blocked by STX molecules; (C) NaV
channels partially blocked by N-sulfocarbamoyl C1 toxin. Here the steric hindrance effect and negative
charge of the N-sulfo-groups are hampering the complete blockage of all pores, still allowing some
Na+ ions to pass through the non-blocked pores.
6. Evolution of Voltage-Gated Na+ Ion Channels and Guanidinium Toxin Genes
The evolutionary history of NaV io chan els and the phylogen tic origin f the guanidinium
toxins pose challenging questions for understanding the fun tional role of these toxins, particularly
with respect to vertebrat nerv us systems. Molecular genetic evidence indicat s that the evolution
of NaV channels predates the origin of the nervous system present in all animals, except for Porifera
(sponges) and primitive basal proto-metazoans (i.e., the putative eumetazoan sister group Placozoa).
Voltage dependent calcium (Cav) channels apparently developed even earlier in unicellular eukaryotes
(Protista), where they play a critical role in intracellular signaling pathways, as for multicellular
organisms. The Cav and NaV channels share key features, such as the presence of four domains, each
of which has a pore loop. The correlating hypothesis is that NaV channels were derived from Cav
channels at the origin of the nervous system [90], thereby conferring the ability to conduct action
potentials without interfering with intracellular calcium fluxes. This hypothesis is also consistent
with the apparent lack of sodium ion currents in sponges [91]. Empirical support for this hypothesis
and unique insights into the evolution of voltage-gated ion-channel genes was provided by in silico
genomic and gene expression sequence analysis of ion channel protein genes of basal animals and their
close unicellular relatives, including fungi—essentially confirming this evolutionary relationship [92].
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The evolution of NaV ion channels in vertebrates involves increasing complexity and refinements
in neuromuscular coordination, and hence more sensitivity and susceptibility to interference with the
generation of action potentials by guanidinium toxins. Adaptive sequence evolution in NaV channels
reveals patterns of increasing complexity, specialization and diversity (reviewed by [93]), particularly
among vertebrates. The primary targets of guanidinium toxins are NaV channels, at least in term of
relative potency, but STX may also act on Ca2+- and human hERG K+ channels (cited in [53]), although
in the latter case by modifying K+ channel gating rather than by blocking the channel. Neuromuscular
responses in invertebrates tend to be more Ca2+- ion channel dependent, and they possess alternative
channels (both NaV1 and NaV2) rather than the exclusive NaV1 family in vertebrates [93]. For these
reasons, and the consequent relative insensitivity to guanidinium toxins, bivalve mollusks and certain
other invertebrates can sequester a body burden of PSTs that would prove lethal to vertebrates, often
with little apparent physiological effect. The response to guanidinium toxins mediated by NaV ion
channel interference is highly species-specific, but conduction of action potentials in the nerves of
certain bivalve mollusks persists even after prolonged exposure to high concentrations of TTX or
STX [94]. Nevertheless, deleterious effects, e.g., inhibition of burrowing behavior and siphon retraction
in the soft-shell clam Mya arenaria [95], can be elicited in some cases. In fact, adaptive evolution of toxin
resistance in populations of M. arenaria chronically exposed to blooms of PST-producing dinoflagellates
is evidenced by mutation of the NaV channel protein via a single amino acid substitution from Glu
to Asp in the outer pore loop [95], thereby conferring a 1000-fold decrease in toxin affinity to the
binding site.
The evolutionary history of the vertebrate NaV is a fascinating story which can only be briefly
referenced here, with respect to evolution of TTX resistance. Essentially, this first involves extensive
channel gene duplication including NaV1 and selective retention in teleost fish and terapods [85].
The complexity of multiple NaV channel genes in vertebrates poses a fundamental question as to the
development of TTX resistance (against auto-toxicity) in amphibians (frogs and newts) and toxigenic
fish, such as Fugu and other puffer fishes. The leading hypothesis contends the gradual accumulation
of resistance via adaptive gene mutations in the NaV channels [85]. Predator-prey interactions between
sympatric versus non-sympatric garter snakes and toxigenic newts are also suggestive of parallel
evolution of TTX-resistance in independent populations and species of resistant snakes. Sequences of
expressed NaV1.4 channels encoded by the scn4a gene reveal corresponding amino acid substitutions
in the TTX binding site pore [96].
In the context of ion-channel interactions with guanidinium toxins it is instructive to consider
the probable evolutionary origins of the biosynthetic genes in cyanobacteria and dinoflagellates.
Although current speculation is that the biosynthetic genes for STX arose first in bacteria, there is
no conclusive evidence that extant bacteria other than certain cyanobacterial species are capable of
synthesizing these toxins. The first putative STX biosynthetic gene cluster (sxt) was identified in
the cyanobacterium Cylindrospermopsis raciborskii T3 [97] and minor gene cluster variants were later
confirmed in other cyanobacteria, including Anabaena circinalis AWQC131C and Aphanizomenon sp.
HN-5 [98,99]. A core set of 14 genes (sxtA-sxtI, sxtP-sxtR, sxtS and sxtU) were originally found among
PST-producing cyanobacteria, and about a dozen more variable elements of the sxt gene cluster have
been subsequently identified. Presence or absence of individual elements of the gene cluster can
account for the toxin composition profile differences among strains and species [100].
Comparative phylogenomic analysis of draft genomic assemblies of putative sxt genes in various
filamentous cyanobacteria [101] suggests the biosynthetic genes were derived via multiple horizontal
gene transfer (HGT) events from alternative origins, including precursor bacteria, and accompanied
by subsequent coordination within and among multiple cyanobacterial lineages. Under this scenario,
the establishment of ancestral toxigenic strains within filamentous cyanobacteria was succeeded by
widespread and common loss of the relevant genes, and hence the patchy distribution of toxigenicity
among extant cyanobacterial lineages.
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This phylogenomic evidence from toxigenic cyanobacteria leaves open the questions as to
whether or not the development of STX gene homologs in dinoflagellates arose via single or multiple
HGT events directly from STX-producing cyanobacteria or independently, perhaps from bacterial
precursors. Close homologs of the cyanobacterial genes were later identified as nuclear-encoded
genes in the PST-producing dinoflagellates Alexandrium fundyense (now renamed A. catenella) and
A. minutum [102]. This similarity led to the hypothesis that the biosynthetic genes arose via horizontal
gene transfer (HGT) between ancestral STX-producing bacteria and dinoflagellate nuclei. Nevertheless,
comparative analysis of the structure and assembly of respective STX gene clusters in cyanobacteria
and dinoflagellates indicates enough dissimilarity to suggest some independent evolution. The fact
that among dinoflagellates, PSTs are produced by two genera within one family (Alexandrium and
Pyrodinium) and by a single species from a distant dinoflagellate order (Gymnodinium) does tend
to indicate that such bacteria-to-dinoflagellate horizontal gene transfer would likely have taken
place prior to the separation of the gonyaulacoid genera Alexandrium and Pyrodinium. Under this
scenario, this event was followed by a dinoflagellate-to-dinoflagellate horizontal gene transfer into
G. catenatum [102].
Whether or not the evolution of NaV ion channels reflects the functional role of guanidinium
toxins and the evolution and maintenance of the corresponding biosynthetic genes in cyanobacteria
and dinoflagellates remains unknown. The origin of filamentous bacteria dates back to at least 2800 Ma,
and molecular genetic evidence proposes the emergence of the sxt gene cluster by before 2100 Ma,
early in the divergence of the Nostocales [103]. The proposed adaptive advantage of STX analogs in
mediating Na+ ion regulation and transport in extant toxigenic cyanobacteria from fresh and brackish
waters [104,105] is consistent with this functional role. Indeed is it conceivable that the pre-Cambrian
precursor to NaV channels-primitive voltage dependent K+ (Kv) ion channels—may have been the
ancestral target for the guanidinium toxins [103]. Potassium leak and Kv ion channels originated
3000 Ma in bacteria [93] and are present in all prokaryotes and eukaryotes. Under this interpretation,
the osmoregulatory effect on Na+/K+-ATPases and proton pump H+-ATPases (reviewed in [106]),
for regulation of salinity/cell volume and pH equilibrium, respectively, could have been crucial
to the co-evolutionary development of biosynthetic genes for PSTs and susceptible ion-channels in
cyanobacterial lineages.
The evolutionary history of the toxigenic dinoflagellates, as for other eukaryotes, is rather different
from cyanobacteria and involves many unresolved complexities, not least of which involves the shared
elements of the sxt gene cluster. The extensive fossil record of dinoflagellates extends back at least
245 Ma to include the Mesozoic and Cenozoic eras, but molecular phylogenetic analysis of modern
dinoflagellates and morphological evidence (e.g., probable homology with acritarchs) suggests an even
earlier Precambrian (>570 Ma) origin [107]. Morphotypes consistent with gonyaulacoid dinoflagellates
first appear in the fossil record of the early Mesozoic, but the fossil record of extant dinoflagellates
known to produce guanidinium toxins extends only back around 10,000 years. Molecular genetic
evidence on the Alexandrium tamarense species complex proposes a molecular clock that splits the
toxigenic group at about 23 Ma [108]. The fossil record and inferences from phylogenomic analysis,
primarily of rDNA genes, tend to suggest an ancient paraphyletic origin for biosynthesis genes for
guanidinium toxins in dinoflagellates, but with more recent secondary loss of biosynthetic capacity at
the generic and specific level. Current hypotheses on the origin of the biosynthetic genes for PSTs in
dinoflagellates-autonomous toxin production by symbiotic bacteria; convergent evolution; single or
multiple HGT events—were elegantly presented in a recent comprehensive review [109] and hence
the arguments will only be briefly summarized here. Empirical evidence for the production of PSTs
by endosymbiotic or externally associated bacteria has been substantially weakened by the failure to
confirm the synthesis of these toxins in isolated bacteria and by the confirmed location of the sxt gene
cluster in the dinoflagellate nuclear genome. The hypothesis that convergent evolution of biosynthetic
genes may account for their occurrence in phylogenetically unrelated dinoflagellates and cyanobacteria
remains open because of the shared domain structures of the sxtA [102] and sxtG [110] core genes.
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Nevertheless, the occurrence of multiple sxt homologs with high sequence identity [110,111] renders
this convergent origin hypothesis unlikely in such highly phylogenetically unrelated groups that
lack a common ancestor. Hence, single- or multiple-HGT of biosynthetic genes to dinoflagellates
from Proteobacteria and/or cyanobacteria remain as the most likely scenarios (reviewed in detail
by [109]). In fact, half of the known dinoflagellate sxt homologs are linked to probable proteobacterial
origin [111], although no extant strains are known to biosynthesize these toxins. The collective evidence
argues for evolution of the STX biosynthetic genes in cyanobacteria prior to the massive HGT of the
initial pathway genes (sxtA, sxtG and sxtB) to the dinoflagellates. In this scenario, the dinoflagellate
ancestor of the extant toxigenic gonyaulacoid dinoflagellates Alexandrium/Pyrodinium then acquired
and assembled the additional genes in the pathway from multiple prokaryotic sources (but not
from cyanobacteria). The STX pathway genes were subsequently modified and incorporated into a
“eukaryotic structure”, and were subject to loss or acquisition among multiple dinoflagellate lineages
to yield a paraphyletic distribution.
Irrespective of the complex evolutionary history of the origin of the guanidinium toxins,
the functional role and putative interactions of these ion channel blockers in cyanobacteria versus
dinoflagellates remains an intriguing question. In contrast to the PST-producing cyanobacteria, which
are typically found in fresh or brackish waters, the toxigenic dinoflagellates are exclusively marine,
and there is little evidence for an important role for these toxins in Na+ ion equilibration in response to
salinity or pH shifts. In fact, the multiple hypotheses for the putative chemical ecological role of PSTs in
dinoflagellates (reviewed by [112]) include sequestration of nitrogen, cell communication, pheromone
activity and ion channel regulation, but allelochemical defense against grazers or microeukaryote
competitors is most often invoked. If chemical defense, particularly against metazoan grazers, is indeed
the primary function of these compounds in dinoflagellates, this implies that the evolutionary function
and selective pressure on the biosynthetic genes may already have diverged from the cyanobacteria.
In that case, the potent effects on the NaV ion channels of the highly evolved neuromuscular systems
of marine mammals, sea birds, teleost fish and human consumers of toxic seafood must be viewed as
“collateral damage” in the chemical arms race—but not of evolutionary adaptive significance.
7. Guanidinium Toxins as Ion Channel Research Subjects and Tools
7.1. Diagnostic Detection Assays for Guanidinium Toxins
Purified guanidinium toxins were first used as research tools to investigate the properties of
ion-conducting membrane proteins, but are now more widely employed for calibration of chemical
instrumental analysis and assay detection methods for food safety surveillance programs. Chemical
analytical methods, based on the physicochemical characteristics of the molecules, are rapidly
replacing the intraperitoneal mouse bioassay (MBA) [113,114] for routine screening of guanidinium
toxins [115]. Such instrumental analytical methods are, in general, time consuming, and require
expensive equipment and infrastructure, and a high level of technical expertise, but they provide
specific qualitative and quantitative information on the toxin composition and chemical structures.
The major drawbacks are that novel toxins and unknown toxin analogs will be missed by these
techniques, and the lack of a complete spectrum of all potential toxins for instrumental calibration
(and hence knowledge of their specific potency) hampers accurate calculated estimates of toxicity.
Biological and biochemical in vitro assay methods for guanidinium toxins offer an alternative
to whole animal bioassays and chemical analytical techniques albeit with only semi-quantitative
detection [116,117]. Diagnostic assays for guanidinium toxins can be sub-divided into two general
categories, depending upon their mode of detection: functional assays, such as the receptor binding
assay (RBA), reflect the relative affinity of the toxin analogs and mode of action for in vivo systems,
whereas structural assays, such as immunoassays and enzyme-inhibition assays, are based upon
biochemical recognition of structural features of the toxin analogs that may or may not correlate well
with respective ion-channel binding affinities. For routine toxin monitoring programs these assay
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methods are often configured as rapid diagnostic kits, and used only for screening presence/absence
of the toxin group or to indicate when toxin levels exceed the regulatory limit. Such in vitro assay
techniques can be configured in a parallel and/or multiplex format for high throughput screening
of putatively toxic samples. Typically, application and interpretation of the assay techniques does
not require a high level of technical expertise or large capital investment in diagnostic detection
systems [118]. While there is intensive research on optimization and configuration of alternative
assay formats for routine toxin screening of toxin contaminated seafood, the role of diagnostic
assays for elucidation of toxin binding mechanisms and ion channel research is rather more limited.
One disadvantage of these methods is that it is not possible to differentiate among toxins that share
the same mechanism of action, and thus the identity of the active molecules will remain unknown.
Detection of different guanidinium analogs may relate to their specific ability to interact with the
receptor, but in most cases, these tools will only provide an overall estimate of general toxicity.
The receptor binding assay (RBA) for guanidinium toxins was originally developed as a specific
research tool for determination of toxin kinetics and estimation of NaV channel densities in excitable
membranes. Given the need for simple and sensitive methods for detection of guanidinium toxins,
attention was directed to development of alternative RBA techniques based upon NaV ion channel
activation/blockage by applying pharmaceuticals. Veratridine—a neurotoxic alkaloid from plants
of the Liliaceae family—was known to cause persistent activation of NaV channels, but this activity
was shown to be blocked by TTX [119,120]. Application of either TTX or STX counteracted the effect
of ouabain inhibition of Na+-K+ ATPase in neuroblastoma cell membranes by blocking the NaV
channel [121]. With this knowledge, Kogure et al. [122] developed an assay for guanidinium toxins
which involved veratridine to activate NaV channels and ouabain to inhibit the effect on Na+-K+
ATPase in neuroblastoma cells. This treatment resulted in visible cell swelling and rounding up,
with loss of osmoregulatory function leading to eventual cell lysis. This uncontrollable increase
in intracellular Na+ concentration was counteracted by the inhibitory effect of TTX or STX in a
concentration-dependent manner.
Later refinements of the Neuro-2A neuroblastoma cell toxicity assay into a microwell plate
format for scanning absorbance of a stain (crystal violet) incorporated into intact neuroblastoma
cells showed high comparability to the AOAC mouse bioassay, but with higher sensitivity, for
PST-containing extracts of dinoflagellates (Alexandrium spp.) and shellfish tissues [123]. A similar
format demonstrated suitable applicability for semi-quantitative rapid screening and detection of PST
analogs produced by cyanobacteria, with good correlation with chromatographic methods for known
toxins [124]. An alternative fluorimetric microplate assay as a quantitative RBA employs a fluorescent
stain (bis-oxonol), with toxin-dose dependent inhibition of depolarization by veratridine [125].
In recent configurations, the RBA has been designed as a competitive radioligand binding assay
with a radio-labelled active molecule (e.g., STX or TTX) applied to a rat brain membrane preparation
containing a known number of available receptor sites. With this approach, competitive detection has
been achieved with 3H-labelled guanidinium toxins (usually STX or TTX) [117,126,127]. The extremely
high affinity of guanidinium toxins for their molecular target (in the nanomolar range) is usually
directly proportional to their in vivo toxic potency, yielding good estimates of their respective toxicity.
An evaluation of binding affinities of different STX analogs yielded toxin potency estimates that closely
tracked those calculated with the AOAC mouse bioassay [128] and this functional assay is now an
AOAC certified detection method for STX [129]. The use of 11-[3H]-TTX has also been validated as an
alternative radio-ligand to STX in a heterologous receptor binding assay for PSTs [130]. Modifications
to the original technique have increased the efficiency of the assays by automated scintillation counting
in individual vials [131] or with microplates [132].
The radio-label approach remains the most common RBA configuration for guanidinium toxins,
but the availability of 3H-labelled ligand has not always been consistent. The requirement for
radioisotopes and handling facilities for their use has been an impediment for many laboratories
and jurisdictions, although the International Atomic Energy Agency (IAEA) continues to provide
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global support and encouragement for the application of this method, particularly in developing
countries where analytical instrumentation and technical expertise for toxin analysis is often lacking.
7.2. Biomedical and Therapeutic Application of Guanidinium Toxins
Natural toxins and venoms have been used in traditional remedies since ancient times,
but research on the specific potency, mode of action and secondary effects of natural bioactive molecules
as pharmaceuticals has developed only within the last 60 years. The intensive research on guanidinium
toxins as potential therapeutants has focused on their ion-channel blocking activity, but the scope
has been limited due to their known high acute toxicity [45] and relative lack of knowledge on
chronic effects.
Chronic pain treatment has been declared a global health priority, but the multivariate causes,
such as cancer, diverse nerve injuries or nerve damage, rheumatoid arthritis, among others, creates
a complexity of syndromes that is difficult to treat. Conventional pain control medications all have
potentially critical secondary effects, especially when administered in high dosages and for extended
periods. In particular, natural and synthetic opioids have been increasingly prescribed to manage
long-term chronic pain, but this has led to higher rates of opioid use disorders and drug abuse [133,134],
as well as overdose deaths [135,136]. Nevertheless, for some patients, opioids are the only viable
pain-management medications at this time.
The functional effects of guanidinium toxins on ion-channel blockage and desensitization have
guided potential application in pain management. Given the fact that they do not cause myocardial
depression or arrhythmias because they do not bind significantly to NaV 1.5 channels, the main
sodium channel in the heart [137], allows the possibility of effective application in pain management.
Furthermore, these toxins have been shown to be benign to nerves and muscle tissues [138], and there
is no evidence of acclimation that could lead of addiction as with opioids, providing additional
encouragement for use in pain control strategies.
Some studies in rabbits have demonstrated that the application of TTX produces local anesthesia
that allowed corneal surgery in rabbits [139], and for systemic analgesic treatments for long-term
pain with neuropathic features [137,138,140]. In combination with the local anesthetic bupivacaine
or the neurotransmitter epinephrine, these drugs reduce the systemic toxicity of TTX and hence the
lethal dose but also yield an intensification of its potency for sensory blockade [137]. Nevertheless, in
spite of evidence of only mild toxicity after administration for pain relief for longer than two weeks,
results were positive for only 17 of 31 human patients [141]. This indicates that the mechanisms of the
analgesic effect and the causes of individual variation remain poorly understood.
Certain purified STX analogs have also been applied as therapeutants and have shown considerable
success in recent medical trials. An epimeric mixture of gonyautoxins 2 and 3 (GTX 2/3) (see Figure 2
for reference) has been used in the treatment of chronic and acute anal fissures, by producing a flaccid
paralysis of the anal muscle in a safe and effective way, and thereby reducing healing time [142,143]. This
same GTX mixture was applied to treat tension-type headache (TTH) and as an anesthetic for total knee
arthroplasty (TKA). For TTH, the treatment was by intramuscular injections, causing an immediate
muscle relaxation and pain reduction that lasted for more than 2 months in some cases [144]. Pain
blockage for TKA was achieved by local infiltration, and there were no side effects or adverse reactions
without the use of opioids [145]. Neosaxitoxin, an N-1 hydroxylated STX analog (see Figure 2), has
been used in the treatment of achalasia, a gastrointestinal motility disorder resulting from a failure of
the lower esophageal sphincter that causes dysphagia or chest pain. Local application of this toxin
in small amounts caused sphincter relaxation and paralysis of the muscle, lasting for at least two
days [146]. The same analog has proven effective as a local anesthetic and as a long-acting pain
blocker in the treatment of bladder pain syndrome, by local infiltration of small doses into the bladder
submucosa with no adverse secondary effects over 90 days [147–149].
Apart from pain control, guanidinium toxins have also been explored as potential treatments of
unregulated drug dependence. Studies with rats have found that microinjections of TTX into specific
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brain regions decreased the demand for cocaine-induced stimuli, and helped to increase knowledge
regarding activity and function of drug dependence mechanisms and related brain structures [150].
Recent evidence from experiments on morphine-dependent mice and rats has suggested that TTX could
be valuable in the treatment heroin-dependent human patients [151]. In this fashion, guanidinium
toxins could serve not only as alternatives to opioids in pain management, but also to reduce craving
and dependence of chronic opiate users.
7.3. Molecular Bioinformatics
Computational approaches and imaging tools are being developed and implemented as valuable
techniques for research on ion channels to decipher their ultrastructure, and to understand the binding
properties of guanidinium toxins to their molecular target [39]. To some extent, the development of in
silico bioinformatic tools reflects the necessity to restrict the use of live animal models as test subjects
because of heightened international concerns for animal rights, and also due to high maintenance
and certification costs for facilities where the experimental animals are kept. Beyond these logistical
constraints, there are also clear technological advantages in applying novel molecular imaging tools,
docking and molecular dynamics (MD) as virtual diagnostic probes and to generate testable hypotheses
regarding structural-functional relationships to toxin potency. Access to images generated with great
accuracy through the use of specialized computational software has led to a better understanding of
the three dimensional structures (Figure 7). In the near future these relatively new analytical tools will
even provide specific information at molecular and atomic levels, such as molecular interactions and
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The accuracy of models for computational studies is dependent upon their characteristics to yield
precise free energy calculations [153]. Several NaV models have been proposed to clarify the mode of
action of guanidinium t xins and to interpret experimental data with molecular accur cy [154,155].
These approaches have shown a wider pore on aV c a els when compared to K+ channels, and this
could partially explain why NaV channels provide access of guanidinium toxins to the selectivity-filter
residues [154]. Bioinformatic approaches have already been applied to explore hindrance effects and
electrostatic properties among protein residues and toxins. Yet at present there is still no validated
mammalian model for the NaV channel, simulations have been therefore typically performed with
homology models based on crystal structures of bacterial NaV channels [153,154], but these are not
direct homologs and have a distinct evolutionary origin. Research on crystal structures of mammalian
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ion channels and construction of accurate models is essential because of the structural discrepancies
from bacterial analogs. Unfortunately, there are few crystal structures of such membrane proteins.
In spite of the lack of Na+ channel structural models for humans, rapid advancements in molecular
studies of homologs from other animal nervous systems, such as insects (e.g., cockroach) and the
electric eel have generated novel structural and functional insights. The structure of an NaV from a
eukaryotic organism, the American cockroach Periplaneta americana, has now been fully elucidated [156],
and this will allow the construction of more accurate models for vertebrates. A recent review of Na+
ion channel structural aspects in insects as related to insecticide resistance [157] provides a useful basis
for comparison with mammalian systems. In the electric eel Electrophorus electricus the coding cDNA
sequences of voltage-gated Na+ channel (scn) α-subunit (scna) and β-subunit (scnb) isoforms have been
determined, and the quantification of the mRNA transcript levels in the main electrogenerative organs
served to elucidate differential functional aspects among electrocytes from different tissues [158].
Although the objectives of such Na+ ion channel studies on insecticide resistance and electrogenesis for
predation, defense and sensory detection, respectively, are not strictly applicable to the interpretation
of structural-functional interactions of Na+ blocking toxins in mammals, they could provide templates
for molecular bioinformatic modelling following application of guanidinium toxins, in particular.
Molecular docking tools can reveal the mechanisms involved in binding recognition in great detail,
and in a way that cannot be deduced merely from electrophysiological research [159]. This approach
may allow fast screening of binding interactions with a given protein for many guanidinium analogs
in short time. As NaV bioinformatic models become more accurate, the information obtained with
this approach will be more precise as well. Precision is currently limited [160] because of simplifying
assumptions and the lack of inclusion of several biological parameters, such as lipid membrane
interactions or water barriers. The protein is unrealistically considered as a static structure, with only
the toxin as a dynamic molecule. Optimal free energy (∆G) values are calculated from scoring function
algorithms that depend upon the bonding or non-bonding interactions between the ligand and the
target [161]. With respect to Na+ channel blocking activity, this approach has been applied mainly to
µ-conotoxins [162], small disulfide-rich proteins comprising 14–20 amino acid residues, but which are
structurally and biosynthetically unrelated to the guanidinium toxins. Tikhonov and Zhorov [155]
have performed docking simulations on NaV channel 1.4 with TTX and µ-conotoxins to predict their
optimal orientation and the interaction energy consistent with experimental results; their analysis
suggested that Na+ channels are more similar to K+ channels than expected. This approach has also
provided theoretical information about ligand properties and molecular interactions between STX and
many of their naturally occurring analogs, and the same isoform of the NaV channel [39].
Molecular dynamics (MD) is an alternative approach that evaluates different structural
conformations to provide more precise information, although this approach increases computational
costs and is more time consuming than molecular docking simulations. The first pioneering MD
simulation with the peptide neurotoxin I (SH1) from the sea anemone Stichodactyla helianthus was
conducted in 1991 [163]. A later important step in MD application to NaV channel research was the
generation of homology model simulations of the NaV channel recognition properties towards the
tarantula peptide toxin psalmotoxin-1 [164], which can bind to a particular isoform (ASIC1) of the Acid
Sensing Ion Channel. Although ASICs are proton-gated Na+ channels and open when H+ binds, unlike
the NaV channels involved in recognition of guanidinium toxins, the general MD modelling approach
should be applicable for these non-peptidic toxins. Recent MD simulations have been useful to better
understand the human NaV1.5 channel. For example, Ahmed et al. [165] developed a homology
model refined through MD simulations in the lipid membrane bilayer; they noted the existence of two
potential binding sites for the Na+ ion at the channel selectivity filter. By employing a more refined
technique, called steered molecular dynamics (SMD), they were also able to identify the key residues
related to this process, none of these molecular bioinformatic approaches are sufficient to describe the
exquisiteness of ion channels and their interactions with ligands (pharmaceuticals, toxins, etc.), but
a combination of docking modelling and MD, supplemented with electrophysiological and genetic
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information could be an effective strategy to explain the binding variability properties and chemical
diversity of Na+ channel blockers. This would contribute to a better understanding of the structure
of the channel and assist in defining the molecular mechanisms for drug interactions in finer detail.
Such a comprehensive strategy has yet to be applied to interaction of guanidinium toxins with NaV
ion channels.
8. Conclusions and Future Perspectives
The basic neurophysiology and mode of interactions of guanidinium toxins with NaV ion channels
have been explored for many decades and are rather well understood. Nevertheless, there remain
incremental challenges to scientific knowledge and progress, from the ongoing search for new natural
sources and biosynthetic mechanisms for known and novel structures to potential technological
applications as research tools, e.g., in diagnostic detection systems, and as pharmacological treatments.
Further development and application of advanced chromatographic techniques for toxin analyte
separation and enhanced high resolution detection systems, such as mass spectrometry, supported by
nuclear magnetic resonance (NMR), will yield structural elucidation of novel guanidinium toxins from
cryptic natural sources. Configuration of these analytical systems for surveillance of guanidinium
toxins in food safety regimes is, however, dependent on a reliable supply of putative toxins for
calibration standards and for specific toxicity assays. The toxicity of many recently discovered
guanidinium analogs remains unknown, mostly due to a lack of purified material for analytical
standards and toxicity trials.
Research on marine toxins also faces new challenges, such as the expanding ban on the use of
animals for toxicity testing in many global jurisdictions. Requirements for research and improved
regulatory regimes will lead to further development of analytical standards and instruments, as well as
new assay methods, in particular biologically based functional assays, and in silico bioinformatic tools.
Pharmacological applications of guanidinium toxins have a promising future, as already shown
by encouraging results for pain treatment and wound healing. The exquisite specificity of these toxins
for certain NaV channels, and the relative lack of adverse acute or chronic secondary effects, makes
them valuable molecules for analgesic and anesthetic purposes.
The biggest challenge is to elucidate and understand the cellular functions of guanidinium toxins
within the producing organisms, and to determine their eco-evolutionary significance. The evolution
of NaV channels preceded the development of neurons, and presumably were permeable to both
Na+ and Ca2+ in early metazoans [93]. Yet the co-evolution (if any) of voltage gated ion channels
and biosynthetic genes for guanidinium toxins in bacteria, cyanobacteria and marine dinoflagellates
remains a mystery. To unravel the details, functional assays of NaV channel homologs would help to
elucidate biological functions and the evolutionary pathway of NaV channels. How Na+ selectivity
could have evolved from Ca2+ (and perhaps even earlier from K+) selectivity by sequential mutations
will require further explorations on ion selectivity of these respective channels [92]. Better knowledge
of the NaV channel function will open the door to generation of more accurate hypotheses on ligand
binding interactions of toxins with these respective proteins. After bioinformatic refinements in the
near future, accurate prediction of specific toxicity of known and novel guanidinium analogs will be
feasible with such in silico analyses.
Given that predicted climatic changes may favor proliferation and range extension of toxigenic
marine microalgal and freshwater cyanobacterial blooms through increased water temperatures and
other related climate-driven properties of aquatic systems, it is of critical importance to achieve an
ecological understanding of toxigenic mechanisms. Anthropogenic factors [31,165], including increased
nutrient loading, may enhance chronic exposure to guanidinium toxins via food or drinking water.
The issue of sub-lethal toxin exposure deserves special attention, particularly in the context of pollution
and nutrient loading of freshwater systems for drinking water for humans and livestock. The serious
impacts on human health, aquatic resources and ecosystem functioning caused by guanidinium toxins
require deeper insights into the origin and spreading of the biosynthetic genes for STX and TTX analogs
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in both prokaryotes and eukaryotes. Now that the responsible gene clusters have been identified,
and the biosynthetic pathways have been elucidated, at least for the STX group, metagenomic and
metatranscriptomic analysis will provide the basis for a more reliable predictive risk assessment.
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